Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study.

Lanreotide depot (LAN) for symptomatic control of carcinoid syndrome (CS) in neuroendocrine tumor (NET) patients previously responsive to octreotide (OCT): Subanalysis of patient-reported symptoms from the phase III elect study. Meeting Abstract

sustainable development goals

SDG 03: Good Health and Well-being

publication date

May 20, 2017

webpage

Web of Science

published in

JOURNAL OF CLINICAL ONCOLOGY Journal

volume

35